Increasing Antibiotic Resistance Crisis is a Major Contributor to Infections Acquired by Patients During Hospital Stays; New, More-Expensive Antibiotics to Drive the Nosocomial Drug Market, According to a New Report from Decision Resources

WALTHAM, Mass.-- Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the growing antibiotic resistance crisis, combined with the increasing number of immunocompromised patients and rising numbers of complex medical procedures, is creating a demand for more-effective antibiotics. Nosocomial Infection, a new Pharmacor report from Decision Resources, Inc., finds that new antibiotic agents will be more expensive and the cost of administering them will grow since more treatment failures due to resistance will mean that more patients will have to receive second-line therapies.

"Despite improvements in the prevention and management of nosocomial infections during the past ten years, these infections continue to contribute significantly to morbidity and mortality statistics," said John Lebbos, MD, analyst at Decision Resources. "Although physicians are excited about emerging narrow-spectrum agents that will add to the antibiotic arsenal available to treat multidrug-resistant gram-positive cocci, many remain concerned about the lack of effective drugs that act against multidrug-resistant gram-negative bacilli in development pipelines."

Nosocomial infections, or infections acquired while in the hospital, are responsible for considerable morbidity and mortality among hospitalized patients. These infections represent the principal source of adverse heathcare outcomes in the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) and account for substantial healthcare cost and resource utilization.

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Nosocomial Infection is an Infectious Disease report.

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends.

Source: PRNewswire